What Overstory’s vegetation intelligence reveals about wildfire and outage risk.
Updated
January 15, 2026 8:03 PM
Aerial photograph of a green field. PHOTO: UNSPLASH
Managing vegetation around power lines has long been one of the biggest operational challenges for utilities. A single tree growing too close to electrical infrastructure can trigger outages or, in the worst cases, spark fires. With vast service territories, shifting weather patterns and limited visibility into changing landscape conditions, utilities often rely on inspections and broad wildfire-risk maps that provide only partial insight into where the most serious threats actually are.
Overstory, a company specializing in AI-powered vegetation intelligence, addresses this visibility gap with a platform that uses high-resolution satellite imagery and machine-learning models to interpret vegetation conditions in detail.Instead of assessing risk by region, terrain type or outdated maps, the system evaluates conditions tree by tree. This helps utilities identify precisely where hazards exist and which areas demand immediate intervention—critical in regions where small variations in vegetation density, fuel type or moisture levels can influence how quickly a spark might spread.
At the core of this technology is Overstory’s proprietary Fuel Detection Model, designed to identify vegetation most likely to ignite or accelerate wildfire spread. Unlike broad, publicly available fire-risk maps, the model analyzes the specific fuel conditions surrounding electrical infrastructure. By pinpointing exact locations where certain fuel types or densities create elevated risk, utilities can plan targeted wildfire-mitigation work rather than relying on sweeping, resource-heavy maintenance cycles.
This data-driven approach is reshaping how utilities structure vegetation-management programs. Having visibility into where risks are concentrated—and which trees or areas pose the highest threat—allows teams to prioritize work based on measurable evidence. For many utilities, this shift supports more efficient crew deployment, reduces unnecessary trims and builds clearer justification for preventive action. It also offers a path to strengthening grid reliability without expanding operational budgets.
Overstory’s recent US$43 million Series B funding round, led by Blume Equity with support from Energy Impact Partners and existing investors, reflects growing interest in AI tools that translate environmental data into actionable wildfire-prevention intelligence. The investment will support further development of Overstory’s risk models and help expand access to its vegetation-intelligence platform.
Yet the company’s focus remains consistent: giving utilities sharper, real-time visibility into the landscapes they manage. By converting satellite observations into clear and actionable insights, Overstory’s AI system provides a more informed foundation for decisions that impact grid safety and community resilience. In an environment where a single missed hazard can have far-reaching consequences, early and precise detection has become an essential tool for preventing wildfires before they start.
Keep Reading
METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.